DOCSLIB.ORG

Supplemental Table 1: Summary of Microarray Experiments Arithmetic Mean of Mrna Fluorescence Signals, Expressed As a Ratio Against the Control Channel C A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Table 1: Summary of Microarray Experiments Arithmetic Mean of Mrna Fluorescence Signals, Expressed As a Ratio Against the Control Channel C A Supplemental table 1: Summary of microarray experiments Arithmetic mean of mRNA fluorescence signals, expressed as a ratio against the control channel C A L B l e e M n v E a e r r l b T / n n e t m o o i i o m e t r s s a p n P s i m e i n r s e s s a c r s n s F i s p m a a R l e x D w r o d T E S C D S O SA0001 P49994 Chromosomal replication initiator protein dnaA 1.5 0.10 L 0 SA0002 P50029 DNA polymerase III, beta chain (EC 2.7.7.7) 1.3 0.09 L 0 Hypothetical protein SAV0003 (Hypothetical protein SA0003 Q99XG7 MW0003) 0.9 0.10 S 0 SA0004 P29232 DNA replication and repair protein recF 1.1 0.10 L 0 SA0005 Q99XG6 DNA gyrase subunit B (EC 5.99.1.3) 1 0.09 L 0 SA0006 Q99XG5 DNA gyrase subunit A (EC 5.99.1.3) 1.9 0.10 L 0 SA0007 Q99XG4 Hypothetical protein SAV0007 2.3 0.22 G 0 SA0008 Q99XG3 Histidine ammonia-lyase (EC 4.3.1.3) (Histidase) 3.5 0.31 E 0 Seryl-tRNA synthetase (EC 6.1.1.11) (Serine--tRNA ligase) SA0009 P99178 (SerRS) 1 0.15 J 0 SA0010 Q99XG1 Hypothetical protein SAV0010 0.7 0.11 E 7 SA0010.1 Q99XG0 Hypothetical protein SAV0011 0.5 0.02 S 0 SA0011 Q99XF9 Hypothetical protein SAV0012 0.7 0.13 E 0 SA0012 Q99XF8 Hypothetical protein SAV0013 0.6 0.13 S 7 SA0013 Q99XF7 Hypothetical protein SAV0014 0.9 0.10 T 2 SA0014 Q99XF6 50S ribosomal protein L9 2 0.11 J 0 SA0015 Q99XF5 Replicative DNA helicase 1.3 0.11 L 0 Adenylosuccinate synthetase (EC 6.3.4.4) (IMP--aspartate SA0016 Q99XF4 ligase) (AdSS) (AMPSase) 0.7 0.14 F 0 SA0017 Q99XF3 Response regulator 1.5 0.09 T 0 Histidine kinase YYCG (TWO-component sensor histidine SA0018 Q9XCM6 kinase) 0.7 0.14 T 2 SA0019 Q99XF2 Hypothetical protein SAV0020 0.9 0.10 S 1 SA0020 Q99XF1 Hypothetical protein SAV0021 0.7 0.14 S 1 Hypothetical protein SAV0022 (Hypothetical protein SA0021 Q99XF0 MW0022) 0.7 0.17 R 0 SA0022 Q99XE9 Hypothetical protein SA0022 0.6 0.12 F 1 SA0023 Q9WVW7 Hypothetical UPF0247 protein SAV0024/SA0023 0.6 0.13 S 0 ORF CN050 (Hypothetical protein SA0024) (Hypothetical SA0024 Q9XB68 protein SAV0025) 0.6 0.11 - 0 ORF CN049 (Hypothetical protein SA0025) (Hypothetical SA0025 Q9XB69 protein SAV0026) (Hypothetical protein MW0026) 0.6 0.42 - 0 Replication protein (Truncated replication protein for PUB110 SA0028 Q9XB70 plasmid) 1.2 0.13 - 0 SA0028.1 Q99XE8 Hypothetical protein SAV0030 0.5 0.02 - 0 SA0029 P22490 Plasmid recombination enzyme (Mobilization protein) 1 0.17 - 0 SA0030 Q99XE7 Hypothetical protein SAV0032 2.3 0.11 - 0 SA0031 Q99XE6 Hypothetical protein SAV0033 2.8 0.63 - 0 Bleomycin resistance protein (Bleomycin resistance SA0032 Q99XE5 protein(BRP)) 1.5 0.10 E 0 Aminoglycoside ADENYLTRANSFERASE AADD (Kanamycin SA0033 O87369 resistance protein) (Kanamycin nucleotidyltransferase) 2.8 0.11 - 0 SA0034 P19380 Transposase for insertion sequence-like element IS431MEC 0.4 0.13 L 0 SA0035 Q99XE4 SA0035 protein (Probable HMG-CoA synthase) 0.7 0.16 I 0 Hypothetical protein (GLYCEROPHOSPHORYLDIESTER phosphodiesterase) (SA0036 protein) (GLYCEROPHOSPHORYLDIESTER SA0036 Q9S3K5 PHOPHODIESTERASE) (MW0029 protein) 0.7 0.15 - 0 ORF CN038 (Hypothetical protein SA0037) (Hypothetical SA0037 O54520 protein SAV0040) (Hypothetical protein MW0030) 0.7 0.25 I 0 Penicillin-binding protein 2' (EPIDERMIDIS MECA PBP2) SA0038 Q54113 (Penicillin binding protein 2 PRIME) 0.4 0.13 M 1 SA0039 P26597 Methicillin resistance mecR1 protein 1 0.11 T 4 SA0040 P26598 Methicillin resistance regulatory protein mecI 3.4 0.10 K 0 SA0041 Q99XE2 XylR protein 0.6 1.42 K 0 SA0042 Q99XE1 Hypothetical protein SAV0045 1.1 0.60 P 0 SA0043 Q99XE0 Hypothetical protein SAV0046 0.7 0.22 P 0 ORF N052 (Hypothetical protein SA0044) (Hypothetical SA0044 Q9XB85 protein SAV0047) 1.2 0.11 P 0 ORF CN031 (Hypothetical protein SA0045) (Hypothetical SA0045 Q9XB86 protein SAV0048) 1 0.18 S 0 ORF CN030 (Hypothetical protein SA0046) (Hypothetical SA0046 Q9XB87 protein SAV0049) 0.3 0.14 R 6 ORF N044 (TRUNCATED(RADC) protein) (Hypothetical SA0053 Q9XB90 protein truncated-RADC) 0.8 0.29 L 0 SA0054 Q99XD7 Hypothetical protein SAV0058 1.5 0.16 S 0 ORF N042 (Hypothetical protein SA0055) (Hypothetical SA0055 Q9KX76 protein SAV0059) 0.5 0.22 - 0 SA0056 Q9KX77 ORF N041 (Hypothetical protein SA0056) 1.1 0.16 - 0 Site-specific recombinase (Cassette chromosome SA0057 Q9XB94 recombinase B) 0.7 0.13 L 0 Site-specific recombinase (Cassette chromosome SA0058 Q9XB96 recombinase A) 1.4 0.26 L 0 ORF N031 (Hypothetical protein SA0059) (Hypothetical SA0059 Q9KX82 protein SAV0063) 0.6 0.20 - 0 ORF N030 (Hypothetical protein SA0060) (Hypothetical SA0060 Q9KX83 protein SAV0064) 1.4 0.17 - 0 ORF N029 (Hypothetical protein SA0061) (Hypothetical SA0061 Q9KX84 protein SAV0065) 2.9 0.11 - 0 SA0062 Q99XD6 Transposase-Staphylococcus aureus IS150 (Fragment) 1.2 0.19 L 0 SA0063 Q99XD5 Transposase 1 0.17 - 0 SA0064 P83125 Hypothetical protein SAV0068 0.9 0.76 - 0 Conserved hypotehtical protein (Hypothetical protein SA0065 Q99XD4 SAV0069) 0.3 0.24 S 6 KDP operon transcriptional regulatory protein KDPE SA0066 Q9XBA2 (KDPE(SCCMEC) protein) (Hypothetical protein KDPE) 0.7 0.12 T 0 SA0067 Q99QS9 KdpD(SCCmec) protein (Hypothetical protein kdpD) 1.2 0.14 T 4 Potassium-transporting ATPase A chain (EC 3.6.3.12) (Potassium-translocating ATPase A chain) (ATP phosphohydrolase [potassium-transporting] A chain) SA0068 Q9XBA7 (Potassium binding and translocating subunit A) 3 0.28 - 12 Potassium-transporting ATPase B chain 1 (EC 3.6.3.12) (Potassium-translocating ATPase B chain 1) (ATP phosphohydrolase [potassium-transporting] B chain 1) SA0070 Q9XBA9 (Potassium binding and translocating subunit B 1) 4 0.59 P 7 SA0071 Q99QS7 KdpC(SCCmec) protein 1 0.20 P 0 SA0072 Q99XD3 Hypothetical protein SAV0075 6 0.34 - 0 SA0073 Q99XD2 Hypothetical protein SAV0076 1.5 0.14 - 0 SA0073.1 Q99XD1 Hypothetical protein SAV0077 0.9 0.02 - 0 SA0074 Q99XD0 Hypothetical protein SAV0078 2.6 0.12 - 0 SA0075 Q99XC9 Hypothetical protein SAV0079 2.2 0.12 - 1 ORF N007 (Hypothetical protein SA0076) (Hypothetical SA0076 Q9KX89 protein SAV0080) 2.5 0.15 - 0 ORF CN005 (SA0077 protein) (Hypothetical protein SA0077 Q9XBB4 SAV0081) 2 0.11 R 0 SA0078 Q99XC8 Hypothetical protein SAV0082 1.5 0.11 - 0 ORF N002 (Hypothetical protein SA0080) (Hypothetical SA0080 Q9XBB8 protein SAV0084) 1.1 0.14 R 7 ORF N001 (Hypothetical protein SA0081) (Hypothetical SA0081 Q9XBC0 protein SAV0085) 0.8 0.17 S 0 SA0082 Q99XC6 Hypothetical protein SA0082 0.3 0.17 S 0 Hypothetical protein SAV0087 (Hypothetical protein SA0083 Q99XC5 MW0057) 0.5 0.16 R 0 SA0084 Q99XC4 Hypothetical protein SAV0088 (MW0058 protein) 1.5 0.11 R 0 SA0085 Q99XC3 Probable tRNA-dihydrouridine synthase (EC 1.-.-.-) 0.9 0.12 J 0 SA0086 Q99XC2 Hypothetical protein SAV0090 1.7 0.11 - 2 SA0088 Q99XC0 Hypothetical protein SAV0092 0.6 0.12 - 5 SA0089 Q99XB9 Hypothetical protein SAV0093 0.6 0.13 L 0 SA0090 Q99XB8 Hypothetical protein SAV0094 0.4 0.18 - 4 SA0091 Q99XB7 1-phosphatidylinositol phosphodiesterase precurosr 0.5 0.16 - 0 SA0092 Q99XB6 Hypothetical protein SAV0096 0.2 0.36 - 1 SA0094 Q99XB4 Hypothetical protein SAV0098 0.3 0.23 - 1 SA0095 Q99XB3 Hypothetical protein SAV0099 0.5 0.32 - 1 SA0096 Q99XB2 Hypothetical protein SAV0100 0.2 0.16 - 1 SA0097 Q99XB1 Hypothetical protein SAV0101 1 0.15 K 0 SA0098 Q99XB0 Hypothetical protein SAV0102 0.7 0.10 R 0 Blt-like protein (SA0099 protein) (Hypothetical protein SA0099 Q9F0Z2 SAV0103) 0.2 0.14 G 14 Hypothetical protein SAV0104 (Hypothetical protein SA0100 Q99XA9 MW0080) 1.3 0.09 P 9 SA0101 Q99XA8 Hypothetical protein SAV0105 5.5 0.10 - 0 SA0102 protein (67 kDa myosin-crossreactive streptococcal SA0102 Q99XA7 antigen homologue) 0.6 0.79 S 0 SA0103 Q99XA6 Hypothetical protein SAV0107 0.4 0.13 G 10 SA0104 Q99XA5 Hypothetical protein SAV0108 0.3 0.10 K 0 SA0105 Q99XA4 Hypothetical protein SAV0109 1 0.10 - 4 SA0106 Q99XA3 LctP protein (L-lactate permease homologue) 1.1 0.13 C 13 Immunoglobulin G binding protein A precursor (IgG binding SA0107 Q99XA2 protein A) (Staphylococcal protein A) 1.5 0.20 - 1 Hyothetical protein (SarH1 protein) (Staphylococcal SA0108 Q9KWJ2 accessory regulator A homologue) 2.4 0.74 K 0 SA0110 Q99XA0 Lipoprotein 0.6 0.22 P 9 SA0111 O87491 Lipoprotein SIRA 0.8 0.10 P 0 SA0112 Q99X99 Hypothetical protein SA0112 0.5 0.38 E 0 SA0113 protein (Hypothetical protein SAV0117) (EC SA0113 Q99X98 4.3.1.12) 0.2 0.23 E 0 SA0114 Q99X97 Hypothetical protein SAV0118 0.3 0.39 Q 0 SA0115 Q99X96 Hypothetical protein SAV0119 (MW0092 protein) 0.4 0.28 G 10 SA0116 Q99X95 Hypothetical protein SAV0120 0.3 0.17 Q 0 SA0117 Q99X94 Hypothetical protein SAV0121 0.3 0.22 Q 0 SA0118 Q99X93 Hypothetical protein SAV0122 (MW0095 protein) 0.3 0.13 G 0 SA0119 protein (Hypothetical protein SAV0123) (EC SA0119 Q99X92 4.1.1.20) 0.3 0.20 E 0 SA0120 Q99X91 Hypothetical protein SA0120 (Hypothetical protein MW0097) 0.4 0.74 K 0 SA0121 Q99X90 Hypothetical protein SAV0125 0.4 0.22 - 3 Acetoin(diacetyl) reductase (EC 1.1.1.5) (Acetoin SA0122 Q99X89 dehydrogenase) (AR) (Meso-2,3-butanediol dehydrogenase) 2 0.19 Q 0 SA0122.1 Q99X88 Hypothetical protein SAV0127 0.4 0.02 - 0 SA0123 Q99X87 Hypothetical protein SAV0128 (MW0102 protein) 0.2 0.21 M 0 SA0124 Q99X86 Hypothetical protein SAV0129 0.2 0.18 M 1 SA0126 Q99X84 Hypothetical protein SAV0131 0.4 0.21 - 11 SA0127 Q99X83 Hypothetical protein SAV0132 0.5 0.19 R 13 SA0128 Q99X82 Superoxide dismutase [Mn/Fe] 2 (EC 1.15.1.1) 1 0.19 P 0 SA0129 Q99X81 Hypothetical protein SAV0134 0.6 0.10 - 1 SA0130 Q99X80 Hypothetical protein SAV0135 0.9 0.16 K 0 SA0131 Q99X79 Purine nucleoside phosphorylase 0.6 0.38 F 0 SA0133 Q99X78 Hypothetical protein SAV0137 1.1 0.09 F 13 Phosphopentomutase (EC 5.4.2.7) SA0134 Q99X76 (Phosphodeoxyribomutase)
Load more

Recommended publications
  • Supporting Information High-Throughput Virtual Screening
    Supporting Information High-Throughput Virtual Screening of Proteins using GRID Molecular Interaction Fields Simone Sciabola, Robert V. Stanton, James E. Mills, Maria M. Flocco, Massimo Baroni, Gabriele Cruciani, Francesca Perruccio and Jonathan S. Mason Contents Table S1 S2-S21 Figure S1 S22 * To whom correspondence should be addressed: Simone Sciabola, Pfizer Research Technology Center, Cambridge, 02139 MA, USA Phone: +1-617-551-3327; Fax: +1-617-551-3117; E-mail: [email protected] S1 Table S1. Description of the 990 proteins used as decoy for the Protein Virtual Screening analysis. PDB ID Protein family Molecule Res. (Å) 1n24 ISOMERASE (+)-BORNYL DIPHOSPHATE SYNTHASE 2.3 1g4h HYDROLASE 1,3,4,6-TETRACHLORO-1,4-CYCLOHEXADIENE HYDROLASE 1.8 1cel HYDROLASE(O-GLYCOSYL) 1,4-BETA-D-GLUCAN CELLOBIOHYDROLASE I 1.8 1vyf TRANSPORT PROTEIN 14 KDA FATTY ACID BINDING PROTEIN 1.85 1o9f PROTEIN-BINDING 14-3-3-LIKE PROTEIN C 2.7 1t1s OXIDOREDUCTASE 1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE 2.4 1t1r OXIDOREDUCTASE 1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE 2.3 1q0q OXIDOREDUCTASE 1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE 1.9 1jcy LYASE 2-DEHYDRO-3-DEOXYPHOSPHOOCTONATE ALDOLASE 1.9 1fww LYASE 2-DEHYDRO-3-DEOXYPHOSPHOOCTONATE ALDOLASE 1.85 1uk7 HYDROLASE 2-HYDROXY-6-OXO-7-METHYLOCTA-2,4-DIENOATE 1.7 1v11 OXIDOREDUCTASE 2-OXOISOVALERATE DEHYDROGENASE ALPHA SUBUNIT 1.95 1x7w OXIDOREDUCTASE 2-OXOISOVALERATE DEHYDROGENASE ALPHA SUBUNIT 1.73 1d0l TRANSFERASE 35KD SOLUBLE LYTIC TRANSGLYCOSYLASE 1.97 2bt4 LYASE 3-DEHYDROQUINATE DEHYDRATASE
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Pallavi Subhraveti Ron Caspi Quang Ong Peter D Karp An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_900114035Cyc: Amycolatopsis sacchari DSM 44468 Cellular Overview Connections between pathways are omitted for legibility.
    [Show full text]
  • The Crystal Structure of Novel Chondroitin Lyase ODV-E66, A
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 587 (2013) 3943–3948 journal homepage: www.FEBSLetters.org The crystal structure of novel chondroitin lyase ODV-E66, a baculovirus envelope protein ⇑ Yoshirou Kawaguchi a, Nobuo Sugiura b, Koji Kimata c, Makoto Kimura a,d, Yoshimitsu Kakuta a,d, a Laboratory of Structural Biology, Graduate School of System Life Sciences, Kyushu University, 6-10-1 Hakozaki, Fukuoka 812-8581, Japan b Institute for Molecular Science of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan c Research Complex for the Medicine Frontiers, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan d Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Fukuoka 812-8581, Japan article info abstract Article history: Chondroitin lyases have been known as pathogenic bacterial enzymes that degrade chondroitin. Received 5 August 2013 Recently, baculovirus envelope protein ODV-E66 was identified as the first reported viral chondroi- Revised 1 October 2013 tin lyase. ODV-E66 has low sequence identity with bacterial lyases at <12%, and unique characteris- Accepted 15 October 2013 tics reflecting the life cycle of baculovirus. To understand ODV-E66’s structural basis, the crystal Available online 26 October 2013 structure was determined and it was found that the structural fold resembled that of polysaccharide Edited by Christian Griesinger lyase 8 proteins and that the catalytic residues were also conserved. This structure enabled discus- sion of the unique substrate specificity and the stability of ODV-E66 as well as the host specificity of baculovirus.
    [Show full text]
  • Manual D'estil Per a Les Ciències De Laboratori Clínic
    MANUAL D’ESTIL PER A LES CIÈNCIES DE LABORATORI CLÍNIC Segona edició Preparada per: XAVIER FUENTES I ARDERIU JAUME MIRÓ I BALAGUÉ JOAN NICOLAU I COSTA Barcelona, 14 d’octubre de 2011 1 Índex Pròleg Introducció 1 Criteris generals de redacció 1.1 Llenguatge no discriminatori per raó de sexe 1.2 Llenguatge no discriminatori per raó de titulació o d’àmbit professional 1.3 Llenguatge no discriminatori per raó d'ètnia 2 Criteris gramaticals 2.1 Criteris sintàctics 2.1.1 Les conjuncions 2.2 Criteris morfològics 2.2.1 Els articles 2.2.2 Els pronoms 2.2.3 Els noms comuns 2.2.4 Els noms propis 2.2.4.1 Els antropònims 2.2.4.2 Els noms de les espècies biològiques 2.2.4.3 Els topònims 2.2.4.4 Les marques registrades i els noms comercials 2.2.5 Els adjectius 2.2.6 El nombre 2.2.7 El gènere 2.2.8 Els verbs 2.2.8.1 Les formes perifràstiques 2.2.8.2 L’ús dels infinitius ser i ésser 2.2.8.3 Els verbs fer, realitzar i efectuar 2.2.8.4 Les formes i l’ús del gerundi 2.2.8.5 L'ús del verb haver 2.2.8.6 Els verbs haver i caldre 2.2.8.7 La forma es i se davant dels verbs 2.2.9 Els adverbis 2.2.10 Les locucions 2.2.11 Les preposicions 2.2.12 Els prefixos 2.2.13 Els sufixos 2.2.14 Els signes de puntuació i altres signes ortogràfics auxiliars 2.2.14.1 La coma 2.2.14.2 El punt i coma 2.2.14.3 El punt 2.2.14.4 Els dos punts 2.2.14.5 Els punts suspensius 2.2.14.6 El guionet 2.2.14.7 El guió 2.2.14.8 El punt i guió 2.2.14.9 L’apòstrof 2.2.14.10 L’interrogant 2 2.2.14.11 L’exclamació 2.2.14.12 Les cometes 2.2.14.13 Els parèntesis 2.2.14.14 Els claudàtors 2.2.14.15
    [Show full text]
  • Active Site of Chondroitin AC Lyase Revealed by the Structure Of
    Biochemistry 2001, 40, 2359-2372 2359 Active Site of Chondroitin AC Lyase Revealed by the Structure of Enzyme-Oligosaccharide Complexes and Mutagenesis†,‡ Weijun Huang,§ Lorena Boju,§ Lydia Tkalec,|,⊥ Hongsheng Su,|,# Hyun-Ok Yang,3 Nur Sibel Gunay,3 Robert J. Linhardt,3 Yeong Shik Kim,O Allan Matte,§ and Miroslaw Cygler*,§ Biotechnology Research Institute, 6100 Royalmount AVenue, Montre´al, Que´bec H4P 2R2 Canada, Montreal Joint Centre for Structural Biology, Montre´al, Que´bec, Canada, IBEX Technologies Inc., 5485 Pare Street, Montre´al, Que´bec H4P 1P7 Canada, Department of Chemistry, DiVision of Medicinal Chemistry and Department of Chemical and Biochemical Engineering, The UniVersity of Iowa, 115 South Grand AVenue, PHAR S328, Iowa City, Iowa 52242-1112, and Natural Products Research Institute, Seoul National UniVersity, Seoul 110-460, Korea ReceiVed October 17, 2000; ReVised Manuscript ReceiVed December 18, 2000 ABSTRACT: The crystal structures of FlaVobacterium heparinium chondroitin AC lyase (chondroitinase AC; EC 4.2.2.5) bound to dermatan sulfate hexasaccharide (DShexa), tetrasaccharide (DStetra), and hyaluronic acid tetrasaccharide (HAtetra) have been refined at 2.0, 2.0, and 2.1 Å resolution, respectively. The structure of the Tyr234Phe mutant of AC lyase bound to a chondroitin sulfate tetrasaccharide (CStetra) has also been determined to 2.3 Å resolution. For each of these complexes, four (DShexa and CStetra) or two (DStetra and HAtetra) ordered sugars are visible in electron density maps. The lyase AC DShexa and CStetra complexes reveal binding at four subsites, -2, -1, +1, and +2, within a narrow and shallow protein channel. We suggest that subsites -2 and -1 together represent the substrate recognition area, +1 is the catalytic subsite and +1 and +2 together represent the product release area.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials OH 8 H H8 H C N OH 3 7 3 2 4 H1 1 5 O H4 O 6 H6’ H3 OH H6 H1’ H2 H5 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 ppm 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 ppm Figure S1. 1D 1H spectrum of 1-dglcnac and signal assignments ppm 2.0 H8 2.5 OH 8 H H C N OH 3 7 3 2 4 3.0 1 5 H1 O H5 O 6 H4 H3 OH 3.5 H6 H2 H6’ H1’ 4.0 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.0 ppm Figure S2. 1H-1H TOCSY 2D NMR spectra for 1-dglcnac and signal assignments ppm 3.0 H1 3.2 H5 H4 3.4 H3 3.6 H6 H6’ H2 3.8 H1’ 4.0 4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 ppm Figure S3. 1H-1H COSY 2D NMR spectra for 1-dglcnac and signal assignment ppm -0.02 -0.01 0.00 0.01 0.02 H1’ H6’ H2 H6 H3 H4 H5 H1 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 ppm Figure S4. 1H-1H JRES 2D NMR spectra for 1-dglcnac and signal assignments ppm 20 C8(22.9) 40 OH 8 H H C N OH C2(53.2) 3 7 3 2 4 60 1 5 C6(63.2) C6(63.2) O 6 C1(69.2) C1(69.2) O C4(72.6) C3(77.0) OH 80 C5(82.7) 100 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.0 ppm Figure S5.
    [Show full text]
  • POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii
    POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii http://rcin.org.pl WSKAZÓWKI DLA AUTORÓW Kwartalnik „Postępy Biochemii” publikuje artykuły monograficzne omawiające wąskie tematy, oraz artykuły przeglądowe referujące szersze zagadnienia z biochemii i nauk pokrewnych. Artykuły pierwszego typu winny w sposób syntetyczny omawiać wybrany temat na podstawie możliwie pełnego piśmiennictwa z kilku ostatnich lat, a artykuły drugiego typu na podstawie piśmiennictwa z ostatnich dwu lat. Objętość takich artykułów nie powinna przekraczać 25 stron maszynopisu (nie licząc ilustracji i piśmiennictwa). Kwartalnik publikuje także artykuły typu minireviews, do 10 stron maszynopisu, z dziedziny zainteresowań autora, opracowane na podstawie najnow­ szego piśmiennictwa, wystarczającego dla zilustrowania problemu. Ponadto kwartalnik publikuje krótkie noty, do 5 stron maszynopisu, informujące o nowych, interesujących osiągnięciach biochemii i nauk pokrewnych, oraz noty przybliżające historię badań w zakresie różnych dziedzin biochemii. Przekazanie artykułu do Redakcji jest równoznaczne z oświadczeniem, że nadesłana praca nie była i nie będzie publikowana w innym czasopiśmie, jeżeli zostanie ogłoszona w „Postępach Biochemii”. Autorzy artykułu odpowiadają za prawidłowość i ścisłość podanych informacji. Autorów obowiązuje korekta autorska. Koszty zmian tekstu w korekcie (poza poprawieniem błędów drukarskich) ponoszą autorzy. Artykuły honoruje się według obowiązujących stawek. Autorzy otrzymują bezpłatnie 25 odbitek swego artykułu; zamówienia na dodatkowe odbitki (płatne) należy zgłosić pisemnie odsyłając pracę po korekcie autorskiej. Redakcja prosi autorów o przestrzeganie następujących wskazówek: Forma maszynopisu: maszynopis pracy i wszelkie załączniki należy nadsyłać w dwu egzem­ plarzach. Maszynopis powinien być napisany jednostronnie, z podwójną interlinią, z marginesem ok. 4 cm po lewej i ok. 1 cm po prawej stronie; nie może zawierać więcej niż 60 znaków w jednym wierszu nie więcej niż 30 wierszy na stronie zgodnie z Normą Polską.
    [Show full text]
  • Functional Domain Motions and Processivity in Bacterial Hyaluronate Lyase: a Molecular Dynamics Study
    Functional Domain Motions and Processivity in Bacterial Hyaluronate Lyase: A Molecular Dynamics study Dissertation Zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakult¨aten der Georg-August-Universit¨at zu G¨ottingen Vorgelegt von Harshad Joshi aus Pune, Indien G¨ottingen, 2007 D7 Referent: Prof. Dr. Tim Salditt Korreferent: PD Dr. Helmut Grubmuller¨ Tag der mundlichen¨ Prufung:¨ To my parents and teachers Great things can be achieved by putting small things together. Just like a rope made of grass can be used to tie down a massive mad elephant. (In the hope that this thesis contributes in better understanding of the mother nature.) Contents 0 Prologue xi 0.1 Scope of the thesis . xiii 0.2 Outlineofthethesis .............................. xvi 1 Theory and Methods 1 1.1 Molecular Dynamics simulations - Principle . 3 1.1.1 From Schr¨odinger equation to Molecular Dynamics . 4 1.2 MD simulations in practice . 9 1.2.1 Integration method and time step . 9 1.2.2 Solvent environment . 10 1.2.3 System boundaries . 11 1.2.4 Temperature and pressure coupling . 12 1.2.5 Improving efficiency . 14 1.2.6 Minimisation and equilibration . 16 1.3 Analysis methods . 17 1.3.1 Principal Component Analysis . 17 2 Processivity and Hyaluronidases 21 2.1 Processive Enzymes . 23 2.2 Hyaluronidases . 25 2.2.1 History and physiological importance . 26 2.2.2 Classification of Hyaluronidases and Spn.Hyaluronate Lyase . 27 2.3 Streptococcus Pneumoniae Hyaluronidase (Spn.Hyal) . 28 2.3.1 Choice of Spn.Hyal for processivity study . 29 2.3.2 Structure of Spn.Hyal and its catalytic mechanism .
    [Show full text]
  • Discovery of High Affinity Receptors for Dityrosine Through Inverse Virtual Screening and Docking and Molecular Dynamics
    Article Discovery of High Affinity Receptors for Dityrosine through Inverse Virtual Screening and Docking and Molecular Dynamics Fangfang Wang 1,*,†, Wei Yang 2,3,† and Xiaojun Hu 1,* 1 School of Life Science, Linyi University, Linyi 276000, China; [email protected] 2 Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia, [email protected] 3 Arieh Warshel Institute of Computational Biology, the Chinese University of Hong Kong, 2001 Longxiang Road, Longgang District, Shenzhen 518000, China * Corresponding author: [email protected] † These authors contributed equally to this work. Received: 09 December 2018; Accepted: 23 December 2018; Published: date Table S1. Docking affinity scores for cis-dityrosine binding to binding proteins. Target name PDB/UniProtKB Type Affinity (kcal/mol) Galectin-1 1A78/P56217 Lectin -6.2±0.0 Annexin III 1AXN/P12429 Calcium/phospholipid Binding Protein -7.5±0.0 Calmodulin 1CTR/P62158 Calcium Binding Protein -5.8±0.0 Seminal Plasma Protein Pdc-109 1H8P/P02784 Phosphorylcholine Binding Protein -6.6±0.0 Annexin V 1HAK/P08758 Calcium/phospholipid Binding -7.4±0.0 Alpha 1 antitrypsin 1HP7/P01009 Protein Binding -7.6±0.0 Histidine-Binding Protein 1HSL/P0AEU0 Binding Protein -6.3±0.0 Intestinal Fatty Acid Binding Protein 1ICN/P02693 Binding Protein(fatty Acid) -9.1±0.0* Migration Inhibitory Factor-Related Protein 14 1IRJ/P06702 Metal Binding Protein -7.0±0.0 Lysine-, Arginine-, Ornithine-Binding Protein 1LST/P02911 Amino Acid Binding Protein -6.5±0.0
    [Show full text]
  • Similar Structures to the E-To-H Helix Unit in the Globin-Like Fold Are Found in Other Helical Folds
    Biomolecules 2014, 4, 268-288; doi:10.3390/biom4010268 OPEN ACCESS biomolecules ISSN 2218-273X www.mdpi.com/journal/biomolecules/ Article Similar Structures to the E-to-H Helix Unit in the Globin-Like Fold are Found in Other Helical Folds Masanari Matsuoka 1,2, Aoi Fujita 1, Yosuke Kawai 1,† and Takeshi Kikuchi 1,* 1 Department of Bioinformatics, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga 525-8577, Japan; E-Mails: [email protected] (M.M.); [email protected] (A.F.); [email protected] (Y.K.) 2 Japan Society for the Promotion of Science (JSPS), Ichibancho, Chiyoda-ku, Tokyo 102-8471, Japan † Present address: Division of Biomedical Information Analysis, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi 980-8575, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +81-77-561-5909; Fax: +81-77-561-5203. Received: 6 December 2013; in revised form: 11 February 2014 / Accepted: 13 February 2014 / Published: 27 February 2014 Abstract: A protein in the globin-like fold contains six alpha-helices, A, B, E, F, G and H. Among them, the E-to-H helix unit (E, F, G and H helices) forms a compact structure. In this study, we searched similar structures to the E-to-H helix of leghomoglobin in the whole protein structure space using the Dali program. Several similar structures were found in other helical folds, such as KaiA/RbsU domain and Type III secretion system domain. These observations suggest that the E-to-H helix unit may be a common subunit in the whole protein 3D structure space.
    [Show full text]